|
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
1 |
[GO] |
2023―Jun―30 |
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database |
Hiroka Nakao, Takenao Koseki, Koki Kato, Shigeki Yamada, Naotake Tsuboi, Kazuo Takahashi, Tomohiro Mizuno |
2 |
[GO] |
2022―Sep―12 |
Efficacy and Safety of Anticoagulants for COVID-19 Patients in the Intensive Care Unit: A Systematic Review and Meta-Analysis |
Vina Neldi, Budi Suprapti, Alfian Nur Rosyid |
3 |
[GO] |
2022―Jun―02 |
The Effect of HIV/AIDS Infection on the Clinical Outcomes of COVID-19: A Meta-Analysis |
Yousef Moradi, Marzieh Soheili, Hojat Dehghanbanadaki, Ghobad Moradi, Farhad Moradpour, Seyede Maryam Mahdavi Mortazavi, et al. (+2) Hamed Gilzad Kohan, Mostafa Zareie |
4 |
[GO] |
2022―Apr―02 |
Association Between Vitamin D Levels and Inflammatory Markers in COVID-19 Patients: A Meta-Analysis of Observational Studies |
Robert Hopefl, Mohamed Ben-Eltriki, Subrata Deb |
5 |
[GO] |
2022―Mrz―02 |
Effects of Vitamin D Serum Level on Morbidity and Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis |
Yiyun Hu, Janice Kung, Andrew Cave, Hoan Linh Banh |
6 |
[GO] |
2021―Jul―28 |
Losartan Inhibits SARS-CoV-2 Replication in Vitro |
Reza Nejat, Ahmad Shahir Sadr, Branden Freitas, Jackelyn Crabttree, Scott D. Pegan, Ralph A. Tripp, David Najafi |
7 |
[GO] |
2021―Jul―15 |
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India |
Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Manjhi, et al. (+3) Deependra Kumar Rai, Anjani Kumar, Asim Sarfaraz |
8 |
[GO] |
2021―Mai―22 |
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis |
Bahman Amani, Ahmad Khanijahani, Behnam Amani, Payam Hashemi |
9 |
[GO] |
2021―Mai―17 |
Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |
Mohammad Tasavon Gholamhoseini, Vahid Yazdi-Feyzabadi, Reza Goudarzi, Mohammad Hossein Mehrolhassani |
10 |
[GO] |
2021―Mai―15 |
Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19 |
Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano, Takaaki Abe, Hiroaki Yamaguchi |
11 |
[GO] |
2021―Mai―03 |
Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California’s Central Valley |
Regine Padilla, Jered Arquiette, Yvonne Mai, Gurinder Singh, Kristine Galang, Edward Liang |
12 |
[GO] |
2021―Feb―22 |
Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes |
Ceren Guney, Fatma AKAR |
13 |
[GO] |
2020―Okt―19 |
Assessing the Elevation of Cardiac Biomarkers and the Severity of COVID-19 Infection: A Meta-analysis |
Cucnhat Walker, Subrata Deb, Hua Ling, Zhe Wang |
14 |
[GO] |
2020―Jul―31 |
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2 |
Hamed Gilzad-Kohan, Fakhreddin Jamali |
15 |
[GO] |
2020―Apr―23 |
Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |
Zsuzsanna Suba |
16 |
[GO] |
2020―Apr―05 |
Current Drugs with Potential for Treatment of COVID-19: A Literature Review |
Md Insiat Islam Rabby |